Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 05, 2019 |
Sep. 30, 2019 |
Sep. 20, 2019 |
Sep. 30, 2019 |
Jun. 30, 2019 |
Mar. 31, 2019 |
Sep. 30, 2018 |
Jun. 30, 2018 |
Mar. 31, 2018 |
Sep. 30, 2019 |
Sep. 30, 2018 |
Dec. 31, 2018 |
Dec. 31, 2017 |
Sep. 29, 2019 |
Jan. 02, 2019 |
May 25, 2018 |
|
| Accumulated deficit | $ (10,207,567) | $ (10,207,567) | $ (10,207,567) | $ (7,624,134) | $ (3,859,086) | |||||||||||
| Net Loss | (863,524) | $ (969,077) | $ (750,832) | $ (852,822) | $ (1,206,255) | $ (1,096,798) | (2,583,433) | $ (3,155,874) | (3,765,047) | (1,856,315) | ||||||
| Net cash used in operating activities | (1,236,659) | (3,243,938) | (3,707,914) | (1,654,617) | ||||||||||||
| Cash and cash equivalents | 504,302 | 504,302 | 504,302 | $ 1,740,961 | 2,847,429 | |||||||||||
| Payments made directly by investor for clinical trial costs | 689,168 | |||||||||||||||
| Repayment made directly by investor for clinical trial expenses | 210,832 | |||||||||||||||
| Debt instrument, conversion price per share | $ 2.043 | |||||||||||||||
| Common stock, forfeited | ||||||||||||||||
| Proceeds from sale of convertible notes | 2,580,000 | |||||||||||||||
| Impairment of long-lived assets | ||||||||||||||||
| Right-of-use asset | 238,186 | 238,186 | 238,186 | |||||||||||||
| Lease obligations | $ 244,162 | $ 244,162 | $ 244,162 | |||||||||||||
| Accounting Standards Update 2016-02 [Member] | ||||||||||||||||
| Right-of-use asset | $ 293,198 | |||||||||||||||
| Lease obligations | $ 303,161 | |||||||||||||||
| 8% Senior Convertible Notes [Member] | New and Existing Investors [Member] | ||||||||||||||||
| Debt instrument, interest percentage | 8.00% | 8.00% | 8.00% | |||||||||||||
| 8% Senior Convertible Notes [Member] | New and Existing Investors [Member] | Subsequent Event [Member] | ||||||||||||||||
| Debt instrument, interest percentage | 8.00% | |||||||||||||||
| Proceeds from sale of convertible notes | $ 745,000 | |||||||||||||||
| Two LOC Agreements [Member] | Lenders [Member] | ||||||||||||||||
| Maximum revolving line of credit | $ 1,400,000 | |||||||||||||||
| Line of credit, interest percentage | 8.00% | |||||||||||||||
| Debt instrument, conversion price per share | $ 2.04 | |||||||||||||||
| Debt instrument, conversion terms | Under the LOC Agreements, all funds borrowed will bear an 8% annual interest rate. The lenders have the right to convert all or any portion of the debt and interest into shares of our common stock at a conversion price equal to the lower of (i) $2.04 per share (ii) a price per share equal to a 10% discount to the pre-money valuation of a Qualified Financing or an Equity State Transaction or (iii) at an adjusted price; all as defined in the 8% Senior Note agreement. The lenders will also receive stock purchase warrants on a 1:1 basis to the number of shares of common stock received that have an exercise price equal to the greater of (i) the closing price of our common stock on the date of conversion or (ii) $2.72 per share. | |||||||||||||||
| LOC Agreement One [Member] | Lenders [Member] | ||||||||||||||||
| Maximum revolving line of credit | $ 700,000 | |||||||||||||||
| LOC Agreement Two [Member] | Lenders [Member] | ||||||||||||||||
| Maximum revolving line of credit | $ 700,000 | |||||||||||||||
| Line of Credit Agreements [Member] | CorLyst, LLC [Member] | ||||||||||||||||
| Common stock beneficially owned, shares | 6,859,527 | |||||||||||||||
| Equity method investment, ownership percentage | 17.70% | |||||||||||||||
| Pledge Agreement [Member] | PoC Capital [Member] | ||||||||||||||||
| Maximum revolving line of credit | $ 900,000 | $ 900,000 | $ 900,000 | $ 1,800,000 | ||||||||||||
| Pledge Agreement [Member] | PoC Capital [Member] | Until Certain Milestones Payment [Member] | ||||||||||||||||
| Common stock, forfeited | 396,476 | |||||||||||||||
| Warrants, forfeited | 396,476 | |||||||||||||||
| Prepaid and Other [Member] | ||||||||||||||||
| Repayment made directly by investor for clinical trial expenses | $ 180,119 | |||||||||||||||